New study explores urinary management in people with spinal cord injury
Rethink Medical has contributed to a new study published in Revista ENFURO exploring urinary management and unmet needs among people with spinal cord injury.
Read moreAll news
Manuel Luque appointed CEO of Rethink Medical
Rethink Medical entered 2026 with a renewed leadership structure, with co-founder Manuel Luque assuming the role of CEO from 1 January 2026.
The transition marks a new stage for the company focused on execution, manufacturing readiness, commercial development and bringing T-Control® to healthcare markets.
More news
Rethink Medical presents T-Control® at the 48th Spanish Neuroscience Nursing Congress
Rethink Medical participated in the 48th Congress of the Spanish Neuroscience Nursing Association, sharing the journey from identifying an unmet need in clinical practice to developing a regulated medical device.
Read more
Rethink Medical reaches the minimum target of its 2026 investment round
Rethink Medical reached the minimum target of its 2026 investment round ahead of the initially planned closing date.
Read more